Eravacycline Dihydrochloride

CHEMBL2219414 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

631.5 g/mol

LogP

—

Phase

4

The dihydrochloride salt form of eravacycline, this tetracycline antibiotic blocks bacterial protein synthesis to treat serious abdominal infections caused by drug-resistant organisms. The salt form is used in the intravenous formulation.

Moleküler Ağırlık

631,5000 g/mol

TPSA

194,00 Å²

Etki Mekanizması

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12.Cl.Cl

InChI

InChI=1S/C27H31FN4O8.2ClH/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39;;/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33);2*1H/t11-,13-,20-,27-;;/m0../s1

Molecular Formula

C27H33Cl2FN4O8

HBD / HBA

8 / 11

Döndürülebilir Bağlar

5

Ağır Atomlar

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The dihydrochloride salt form of eravacycline, this tetracycline antibiotic blocks bacterial protein synthesis to treat serious abdominal infections caused by drug-resistant organisms. The salt form is used in the intravenous formulation.

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Yes, Eravacycline Dihydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2219414. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 56951485. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Eravacycline Dihydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C27H33Cl2FN4O8

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Eravacycline Dihydrochloride

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget